Radioactive antibody boosts transplant prep for tough leukemias
NCT ID NCT06287944
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and targeted radiation can safely improve the conditioning regimen before a donor stem cell transplant. The study includes 15 adults with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The goal is to find the best dose and see if the combination helps kill cancer cells more effectively while limiting side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radioactive antibody (225Ac-DOTA-daratumumab) plus chemotherapy (fludarabine, melphalan) and targeted radiation
- What this could lead to
- If successful, this could lead to a more effective and safer conditioning regimen for stem cell transplant in high-risk blood cancers, potentially improving survival.
- What could go wrong
- This is a very early, small phase 1 trial with only 15 participants, so results may not apply broadly. The radioactive antibody may cause serious side effects, and the treatment may not work better than standard approaches.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?